Ghent University Academic Bibliography

Show Sort by

Your filters: cql: keyword exact "Cancer Research"

Add to list
- Journal Article
- A1
Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination

Valeria Tosello, Deborah Bongiovanni, Jingjing Liu, Qingfei Pan, Koon-kiu Yan, Valentina Saccomani, Maaike Van Trimpont (UGent) , Marco Pizzi, Martina Mazzoni, Angelo Paolo Dei Tos, et al.

(2021) LEUKEMIA.
Add to list
- Journal Article
- A1
5-year outcomes of a randomized trial comparing prone and supine whole breast irradiation in large-breasted women

Vincent Vakaet (UGent) , Hans Van Hulle (UGent) , Marie Vergotte, Max Schoepen (UGent) , Pieter Deseyne (UGent) , Annick Van Greveling (UGent) , Giselle Post (UGent) , Bruno Speleers (UGent) , Leen Paelinck (UGent) , Christel Monten (UGent) , et al.

(2021) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS.
Add to list
MYB rearrangements and over‐expression in T‐cell acute lymphoblastic leukemia

Valentina Bardelli, Silvia Arniani, Valentina Pierini, Tiziana Pierini, Danika Di Giacomo, Paolo Gorello, Martina Moretti, Fabrizia Pellanera, Loredana Elia, Antonella Vitale, et al.

(2021) GENES CHROMOSOMES & CANCER.
Add to list
- Journal Article
- A1
- open access
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals

Arne Claeys (UGent) , Tom Luijts, Kathleen Marchal (UGent) and Jimmy Van den Eynden (UGent)

(2021) PLOS Genetics. 17(2).
Add to list
- Journal Article
- A1
- open access
Targeting immunogenic cancer cell death by photodynamic therapy : past, present and future

Razan Alzeibak, Tatiana A. Mishchenko, Natalia Y. Shilyagina, Irina V. Balalaeva, Maria V. Vedunova and Dmitri Krysko (UGent)

(2021) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9(1).
Add to list
Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial

Céleste Lebbé, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey (UGent) , et al.

(2021) TARGETED ONCOLOGY. 16(1). p.47-57
Add to list
Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors

Jean-Pierre Delord, Antoine Italiano, Ahmad Awada, Philippe Aftimos, Nadine Houédé, Céleste Lebbé, Celine Pages, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, et al.

(2021) TARGETED ONCOLOGY. 16(1). p.37-46
Add to list
- Journal Article
- A1
- open access
Immuno-oncological biomarkers for squamous cell cancer of the head and neck : current state of the art and future perspectives

Stijn De Keukeleire (UGent) , Tijl Vermassen (UGent) , Elien Hilgert (UGent) , David Creytens (UGent) , Liesbeth Ferdinande (UGent) and Sylvie Rottey (UGent)

(2021) CANCERS. 13(7).
Add to list
Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors

Matthew D. Hellmann, Nicoletta Bivi, Boris Calderon, Toshio Shimizu, Brant Delafontaine (UGent) , Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, F. Stephen Hodi, Sylvie Rottey (UGent) , et al.

(2021) CLINICAL CANCER RESEARCH.
Add to list
- Journal Article
- open access
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy

Emily De Lombaerde (UGent) , Olivier De Wever (UGent) and Bruno De Geest (UGent)

(2021) Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.

Academic Bibliography

Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination

5-year outcomes of a randomized trial comparing prone and supine whole breast irradiation in large-breasted women

MYB rearrangements and over‐expression in T‐cell acute lymphoblastic leukemia

Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals

Targeting immunogenic cancer cell death by photodynamic therapy : past, present and future

Selective oral MEK1/2 inhibitor pimasertib in metastatic melanoma : antitumor activity in a phase I, dose-escalation trial

Selective oral MEK1/2 inhibitor pimasertib : a phase I trial in patients with advanced solid tumors

Immuno-oncological biomarkers for squamous cell cancer of the head and neck : current state of the art and future perspectives

Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors

Delivery routes matter: Safety and efficacy of intratumoral immunotherapy

Contents

Support

Contact